ADVM

Adverum Biotechnologies Stock Price

3.74
0.01 (0.27%)
Upgrade to Real-Time
Afterhours (Closed)
3.74

Low
3.34

52 Week Range

High
26.98

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Adverum Biotechnologies Inc ADVM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01 0.27% 3.74 00:00:01
Open Price Low Price High Price Close Price Prev Close
3.7091 3.51 3.74 3.67 3.73
Bid Price Ask Price Spread News
3.74 4.33 0.59 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
19,155 8,512,966 $ 3.61 $ 30,757,026 3,338,848 3.34 - 26.98
Last Trade Time Type Quantity Stock Price Currency
19:58:53 formt 200 $ 3.74 USD

Adverum Biotechnologies Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 366.28M 97.93M 92.21M $ - $ - -1.37 -2.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 40.00k 4.50%

more financials information »

Adverum Biotechnologies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ADVM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.713.7953.513.691,709,1580.030.81%
1 Month3.543.7953.343.532,029,7130.205.65%
3 Months10.1410.853.344.392,839,179-6.40-63.12%
6 Months12.6214.793.346.481,791,095-8.88-70.36%
1 Year24.1726.983.349.571,436,887-20.43-84.53%
3 Years5.5526.982.629.711,153,917-1.81-32.61%
5 Years3.3826.982.408.73876,0330.3610.65%

Adverum Biotechnologies Description

Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients.


Your Recent History
NASDAQ
ADVM
Adverum Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.